
The FDA Just Approved a New Blue Food Dye: This Is What It's Made Of
As the fourth color additive from natural sources approved by the FDA this year, gardenia (genipin) blue has been granted permission to be used in various foods. According to the administration, this blue dye comes from the fruit of the gardenia, a flowering evergreen. It can be used in hard and soft candy, sports drinks, ready-to-drink teas, flavored or enhanced non-carbonated water and fruit drinks and ades.
"This expedited timeline underscored our serious intent to transition away from petroleum-based synthetic dyes in the food supply, said FDA Commissioner Marty Makary in a news release. "Now, by expanding the palette of available colors derived from natural sources, food manufacturers have a variety of options available that will make it easier to end their use of petroleum-based dyes."
Gardenia (genipin) blue joins the red algae-based galdieria extract blue, butterfly pea flower extract and the white color calcium phosphate as 2025's new and approved natural food color additives.
MichelleHow is gardenia (genipin) blue made?
The FDA approved the use of gardenia (genipin) blue from a petition by the Gardenia Blue Interest Group (GBIG). According to the FDA's order, gardenia (genipin) blue is a dark purple or blue liquid made from the mature fruit of the Gardenia jasminoides Ellis plant with soy protein hydrolysate. Now, you may be thinking: Isn't soy an allergen? According to the GBIG, the soy protein allergens aren't expected to be detected in the final color additive because "unreacted protein hydrolysate is removed during manufacturing."
Because no soy protein allergens will be in the final product, the GBIG is asking to be exempt from food allergen labeling. The FDA is currently reviewing this petition.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Axmed and Every Pregnancy announce transformative partnership to enhance access to affordable essential medicines for mothers and babies affected by conflict and crisis
WASHINGTON, July 17, 2025 /PRNewswire/ -- Axmed, a health technology venture revolutionizing access to medicines and health products through an innovative procurement platform, and Every Pregnancy, a global, faith-based coalition that provides health services to mothers and babies affected by conflict and crisis, today announced a strategic partnership to bring affordable, quality medicines to mothers and babies who need them most. Approximately 92% of maternal deaths occur in low- and middle-income countries. In these regions, pregnant women are dying from preventable causes due to lack of access to and high costs of essential medicines and health supplies. Families in low-income countries often pay more than double for the same medicines as families in high-income settings. This new collaboration will provide Every Pregnancy partners access to affordable and quality medicines through Axmed's pioneering B2B marketplace. Together, Every Pregnancy and Axmed will break down systemic barriers that prevent medicines from reaching mothers and newborns – including fragmented supply chains, missed demand, and the limited purchasing power of local NGOs who are best positioned to meet the needs of local populations. "No mother or newborn should die simply because of where they live or how much they earn," said Emmanuel Akpakwu, Founder & CEO of Axmed. "Through our partnership with Every Pregnancy, we're combining cutting-edge procurement and supply technology with a powerful network of frontline maternal health providers to drive systemic change – faster, smarter, and at the scale this crisis demands." Through its tech-enabled procurement platform, Axmed aggregates demand from public, private, and nonprofit health care procurers, enabling bulk purchasing directly from qualified manufacturers and drastically reducing costs and improving the quality of products. By partnering with Every Pregnancy, Axmed extends its platform's reach and impact in over 20 countries with high burdens of maternal mortality – including Nigeria, Sudan, Pakistan, Palestine, and more. "This is what it looks like when community power and innovation work hand-in-hand," said Isra Chaker, CEO of Every Pregnancy. "Our collaboration with Axmed is about more than access – it's about equity, justice, and building responsive health care systems that save lives." The Axmed–Every Pregnancy partnership marks a turning point in equitable health care delivery for moms and babies, so that one day, every mother and child will have access to the quality care they deserve. About Axmed: Axmed is a technology-enabled marketplace revolutionizing how medicines and health products are sourced, financed, procured, and delivered across low- and middle-income countries. By digitizing large-scale procurement and aggregating demand across diverse procurers, Axmed enables direct access to a trusted network of local and international prequalified suppliers. Visit About Every Pregnancy: Every Pregnancy is a faith–inspired initiative committed to ensuring safe pregnancies and healthy newborns in areas impacted by conflict or crisis. The organization unites a coalition of over 40 faith–inspired philanthropists and NGOs across the U.S., U.K., Canada, Pakistan, Yemen, and beyond. Visit Media inquiries: info@ or comms@ Photo - View original content to download multimedia: SOURCE Axmed; Every Pregnancy Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Castle Biosciences Honored with Multiple Top Workplaces Awards Recognizing the Company's Strong Culture
Castle earns recognition as a national Healthcare Industry Top Workplace, an Arizona Top Workplace and receives five Top Workplaces Culture Excellence awards FRIENDSWOOD, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned multiple awards through the 2025 Top Workplaces program: a third consecutive national Healthcare Industry Top Workplaces award, with Castle ranking third among other recognized companies in its size bracket; a fourth consecutive regional Arizona Top Workplaces award from AZ Central; and consecutive national Top Workplaces Culture Excellence awards for Innovation, Work-Life Flexibility, Compensation & Benefits, Leadership and Purpose & Values. 'Being recognized as a Top Workplace, year after year, demonstrates the incredible strength of our Castle team and commitment to our shared mission to improve health through innovative tests that guide patient care,' said Derek Maetzold, president and chief executive officer of Castle Biosciences. 'These employee-driven honors affirm that our people-first culture isn't just a philosophy, but a catalyst that helps fuel our innovation and impact.' Top Workplaces awards recognize organizations that have built exceptional workplace cultures, with regional and industry awards celebrating employers of choice within specific areas, and culture excellence awards highlighting organizations that excel in particular aspects of workplace culture. Award designations are garnered solely through anonymous employee feedback gathered through a third-party survey administered by Energage. The confidential survey measures the workplace experience and various culture themes that are indicative of successful organizations, such as employees feeling 'fairly valued,' 'engaged,' and 'respected and supported.' Castle's receipt of the Top Workplaces Culture Excellence awards listed below underscores its strong, people-first culture and provides distinction in the following areas: Innovation (2022-2025), for embedding innovation into its culture and creating an environment where new ideas come from all employees. Work-Life Flexibility (2023-2025), for building a culture that enables employees to meet the demands of their personal lives while maintaining high performance. Compensation & Benefits (2022-2025), for providing employees not only with material rewards but also with appreciation for their work. Leadership (2022-2025), for organizational leaders who inspire confidence in their employees and in the direction of the company. Purpose & Values (2022-2025), for successfully communicating the company mission and integrating those aspirations into the culture. About Castle BiosciencesCastle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle's current portfolio consists of tests for skin cancers, Barrett's esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit and connect with us on LinkedIn, Facebook, X and Instagram. DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc. Investor Contact:Camilla Zuckeroczuckero@ Media Contact:Allison Marshallamarshall@
Yahoo
11 minutes ago
- Yahoo
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
Harrow to assume full commercial responsibility for BYOOVIZ® and OPUVIZ™ by the end of 2025 NASHVILLE, July 17, 2025--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter "Samsung Bioepis") to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar referencing EYLEAii (aflibercept) — two of the most widely used anti-VEGF therapies for retinal diseases. BYOOVIZ has been commercialized by Biogen in the U.S. since its initial launch in June 2022. In October 2024, Biogen notified Samsung Bioepis of their decision to terminate the 2019 Development and Commercialization Agreement within the U.S. and Canada. Samsung Bioepis has been closely working with Biogen on the transfer of commercialization rights for BYOOVIZ and OPUVIZ back to Samsung Bioepis in these regions. Harrow will assume full responsibility for commercialization of BYOOVIZ in the U.S. upon completion of the transition of commercial rights from Biogen back to Samsung Bioepis. The transition is expected to be completed by the end of 2025. This strategic acquisition enhances Harrow's position as the leading full-spectrum ophthalmic pharmaceuticals provider in the U.S., expands its pipeline with high-value biosimilars for sight‑threatening retinal diseases, and reinforces its commitment to delivering value-oriented innovation to the U.S. eyecare market. "This transformational acquisition marks a pivotal moment for Harrow and reinforces our commitment to delivering innovation, accessibility, and value to the U.S. ophthalmology community," said Mark L. Baum, Chairman and Chief Executive Officer of Harrow. "We are excited to leverage our growing commercial presence within the retina specialist community, built over the past year, and partner with Samsung Bioepis, globally recognized for its scientific excellence in biologics and biosimilars. These ophthalmic assets are among the most highly regarded in the market, and we are looking forward to bringing these products to U.S. physicians and patients." Transaction Highlights Acquired Rights: Harrow gains exclusive U.S. commercial rights to Samsung Bioepis' portfolio of ophthalmic biosimilars, including BYOOVIZ® ("bio-viss") and OPUVIZ™ ("op-u-vis"): BYOOVIZ (ranibizumab-nuna) 0.05mL injection, the first FDA-approved LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV). OPUVIZ (aflibercept-yszy) 0.05mL injection, an FDA-approved EYLEA biosimilar indicated for the treatment of patients with Wet AMD, Macular Edema following RVO, Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). Market Opportunity: The retinal disease treatment market represents a $9 billion opportunityiii in the U.S., with biosimilars expected to expand patient access and affordability. Execution-Ready Platform: Harrow will leverage its established commercial infrastructure and national reach to accelerate the market impact of these biosimilars. Harrow is committed to reshaping the Wet AMD treatment landscape by offering an FDA-approved, on-label, and affordable alternative to existing anti-VEGF therapies. The market is dominated by EYLEA, LUCENTIS, VABYSMO, and compounded Avastin, which continues to be used off-label due to its low cost, despite not being formulated or approved for ocular administration. Current anti-VEGF therapies are among the most expensive drug categories covered under Medicare Part B, with annual spending in the U.S. exceeding $4.2 billioniv. Harrow's acquisition of these products has the potential to substantially lower the financial burden on Medicare and commercial plans, while improving access and affordability for patients. About BYOOVIZ (ranibizumab-nuna) BYOOVIZ (ranibizumab-nuna) injection, for intravitreal (ranibizumab-nuna) is biosimilar to LUCENTIS (ranibizumab injection).BYOOVIZ, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:Neovascular (Wet) Age-Related Macular Degeneration (AMD)Macular Edema Following Retinal Vein Occlusion (RVO)Myopic Choroidal Neovascularization (mCNV) Select Important Safety Information WARNING AND PRECAUTIONS Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the in intraocular pressure (IOP) have been noted both pre- and post-intravitreal is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. ADVERSE REACTIONS The most common adverse reactions (reported more frequently in ranibizumab treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP. Please see Prescribing Information for BYOOVIZ (ranibizumab-nuna) HERE. About OPUVIZ (aflibercept-yszy) OPUVIZ (aflibercept-yszy) injection, for intravitreal (aflibercept-yszy) is biosimilar to EYLEA (aflibercept).OPUVIZ is a vascular endothelial growth factor (VEGF) inhibitor, indicated for the treatment of patients with:Neovascular (Wet) Age-Related Macular Degeneration (AMD)Macular Edema Following Retinal Vein Occlusion (RVO)Diabetic Macular Edema (DME)Diabetic Retinopathy (DR) Select Important Safety Information WARNING AND PRECAUTIONS Endophthalmitis, retinal detachments, and retinal vasculitis with or without occlusion may occur following intravitreal injections. Patients and/or caregivers should be instructed to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately. Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. ADVERSE REACTIONS The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased. Please see Prescribing Information for OPUVIZ (aflibercept-yszy) HERE. About Harrow Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC's web site at Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. i Lucentis is a trademark of Genentech, Inc. ii Eylea is a trademark of Regeneron Pharmaceuticals, Inc. iii Company annual reports & Biopharma AVASTIN estimates iv View source version on Contacts Investors:Mike Biega, VP of Investor Relations and Communicationsmbiega@ 617-913-8890Media: Silvana Guerci-Lena, Powers & 508-808-8993